Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

This Phase 2 study is testing a drug called SHR2554 combined with other anti-cancer treatments in people with advanced non-small cell lung cancer (NSCLC). SHR2554 works by targeting a protein called EZH2, which can drive cancer cell growth. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with locally advanced unresectable or metastatic non-small cell lung cancer - Your overall health is good (ECOG score of 0 or 1) - Your expected survival is at least 12 weeks - Your organ function (liver, kidneys, blood) meets study requirements - You are willing to participate and have signed the informed consent form **You may NOT be eligible if...** - You have difficulty swallowing or a gastrointestinal condition that would prevent absorbing the oral medication - You have had a gastrectomy (stomach removal) or gastric banding surgery - You have other serious health conditions that could interfere with treatment Talk to your doctor to see if this trial is right for you.